Nektar Therapeutics Balance Sheet
NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nektar Therapeutics financial position
At the end of fiscal 2025, Nektar Therapeutics reported total assets of $280.4 million, down 7.7% from a year earlier against total liabilities of $190.6 million. Shareholders' equity stood at $89.8 million, or 32.0% of assets. The company held $15.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.97, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Nektar Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 15.12M | 44.25M | 35.28M | 88.23M | 25.22M | 198.96M | 96.36M | 194.91M | 4.76M | 59.64M |
| Short-Term Investments | 230.64M | 210.97M | 268.34M | 416.75M | 708.74M | 862.94M | 1.23B | 1.14B | 291.37M | 329.46M |
| Receivables | — | 0 | 1.21M | 5.98M | 22.49M | 38.89M | 36.80M | 43.21M | 5.01M | 15.68M |
| Inventory | 0 | 0 | 16.10M | 19.20M | 15.80M | 15.29M | 12.66M | 11.38M | 10.73M | 11.11M |
| Total Current Assets | 266.27M | 261.29M | 330.70M | 545.97M | 795.58M | 1.14B | 1.42B | 1.44B | 326.82M | 425.95M |
| Property, Plant & Equipment | 2.06M | 3.41M | 18.86M | 32.45M | 60.51M | 59.66M | 65.67M | 48.85M | 47.46M | 65.60M |
| Goodwill | — | — | 0 | 76.50M | 76.50M | 76.50M | 76.50M | 76.50M | 76.50M | 76.50M |
| Long-Term Investments | 0 | 13.87M | 25.82M | 0 | 64.83M | 136.66M | 279.12M | 582.89M | 57.09M | — |
| Total Assets | 280.41M | 303.85M | 398.03M | 710.60M | 1.12B | 1.54B | 1.98B | 2.15B | 508.87M | 568.87M |
| Accounts Payable | 10.77M | 11.56M | 9.85M | 12.98M | 9.75M | 22.14M | 19.23M | 5.85M | 4.78M | 2.82M |
| Total Current Liabilities | 53.54M | 61.40M | 51.27M | 68.20M | 85.20M | 115.78M | 353.89M | 82.00M | 56.16M | 72.22M |
| Long-Term Debt | — | — | — | — | — | — | 0 | 246.95M | 245.21M | 243.46M |
| Total Liabilities | 190.57M | 243.11M | 267.05M | 343.96M | 437.68M | 461.47M | 571.97M | 432.60M | 421.04M | 480.75M |
| Shareholders' Equity | 89.83M | 60.74M | 130.99M | 366.64M | 679.51M | 1.08B | 1.41B | 1.72B | 87.83M | 88.13M |
| Retained Earnings | -3.76B | -3.60B | -3.48B | -3.20B | -2.83B | -2.31B | -1.86B | -1.42B | -2.12B | -2.02B |
| Total Debt | — | — | — | — | — | — | 0 | 246.95M | 245.21M | 243.46M |
| Net Cash (Debt) | 245.75M | 255.23M | 303.62M | 504.98M | 733.96M | 1.06B | 1.32B | 1.09B | 50.92M | 145.64M |
| Shares Outstanding | 20.38M | 12.39M | 191.38M | 188.56M | 185.47M | 180.09M | 176.50M | 173.53M | 159.52M | 153.21M |
This table shows 10 annual periods of Nektar Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NKTR's reporting calendar. What is a balance sheet?